FDA Accepts New Drug Application for Vascular Ehlers-Danlos Drug
https://pixabay.com/en/drugs-capsule-pill-medicine-2031442/

FDA Accepts New Drug Application for Vascular Ehlers-Danlos Drug

According to a story by MarketScreener, pharmaceutical company Acer Therapeutics Inc. has submitted a New Drug Application (NDA) for its vascular Ehlers-Danlos syndrome (vEDS) drug Edsivo. The NDA was granted…

Continue Reading FDA Accepts New Drug Application for Vascular Ehlers-Danlos Drug

Potential Gene Therapy for Limb Girdle Muscular Dystrophy Type 2D Granted Orphan Drug Designation

Limb Girdle Muscular Dystrophy Type 2D (LGMD2D), also called alpha-sarcoglycanopathy, is a form of muscular dystrophy which is caused by a defected SGCA gene. It causes the body to lose function of…

Continue Reading Potential Gene Therapy for Limb Girdle Muscular Dystrophy Type 2D Granted Orphan Drug Designation
Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Source: Pixabay

Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Thanks to a Phase 2 trial, pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Ph+ ALL, now have a new treatment option. The FDA has announced approval of Sprycel…

Continue Reading Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Chronic Inflammatory Demyelinating Polyneuropathy Didn’t Stop This Woman From Finishing Her 11th Chicago Marathon
skeeze / Pixabay

Chronic Inflammatory Demyelinating Polyneuropathy Didn’t Stop This Woman From Finishing Her 11th Chicago Marathon

According to a story from ESPN, there were times when Lynn Rogers wasn't sure if she was going to be able walk, much less run, ever again, but she wound…

Continue Reading Chronic Inflammatory Demyelinating Polyneuropathy Didn’t Stop This Woman From Finishing Her 11th Chicago Marathon

Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a…

Continue Reading Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH), is condition most commonly caused by obesity or type 2 diabetes. It can result in fibrosis, complications in the lung and cardiac system, liver cancer, liver cirrhosis,…

Continue Reading Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Poll Finds Broad Support For The Use of Gene Editing to Protect Against Genetic Diseases

According to a story from ksl.com, a recent poll found that the majority of Americans are in support of using gene editing technology in order to protect newborns from genetic…

Continue Reading Poll Finds Broad Support For The Use of Gene Editing to Protect Against Genetic Diseases